Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genomic landscape of <i>Candidozyma auris</i> in Italy, 2019 to 2025: emerging diversity of clade I sub-lineages associated with inter-facility transmission and cross-border transfers.

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin·2026
Same author

A randomized clinical trial to compare moxiFloxAcin veRsus aziTHromycin for the trEatment of MycoplaSma geniTalium: the FARTHEST Study.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Targeted peri-operative prophylaxis in patients colonized with Carbapenem Resistant Enterobacterales undergoing Liver Transplantation: a multinational cohort study.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Clinical Spectrum of Children With Parvovirus B19-Associated Acute Myocarditis.

Circulation·2026
Same author

Comparable 5-Year Survival in People With and Without HIV Following Hepatocellular Carcinoma Diagnosis: A Multicenter Study.

Liver international : official journal of the International Association for the Study of the Liver·2025
Same author

Use of isavuconazole in critically ill patients in intensive care units: a prospective, observational, multicentre, cohort study.

JAC-antimicrobial resistance·2025

Related Experiment Video

Updated: May 11, 2026

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

12.5K

Cefiderocol-Based Regimen for Acinetobacter NDM-1 Outbreak.

Giovanna Travi1, Francesco Peracchi1,2, Marco Merli1

  • 1Division of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, 20162 Milan, Italy.

Antibiotics (Basel, Switzerland)
|August 29, 2024
PubMed
Summary
This summary is machine-generated.

Cefiderocol shows promise for treating carbapenem-resistant Acinetobacter baumannii (CRAB) infections, especially NDM-producing strains, achieving high clinical cure rates. However, overall mortality remains high, underscoring the need for susceptibility testing and infection control.

Keywords:
Acinetobacter baumannii complexNDMcefiderocolcolistin

More Related Videos

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

9.0K
Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
11:15

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

4.6K

Related Experiment Videos

Last Updated: May 11, 2026

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

12.5K
A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

9.0K
Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
11:15

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

4.6K

Area of Science:

  • Infectious Diseases
  • Antimicrobial Resistance
  • Clinical Microbiology

Background:

  • Carbapenem-resistant Acinetobacter baumannii (CRAB) poses a significant treatment challenge.
  • Metallo-beta-lactamase (MBL)-producing CRAB strains are particularly difficult to treat.
  • Cefiderocol is a novel antibiotic with activity against Gram-negative bacteria, including some resistant strains.

Purpose of the Study:

  • To describe the outcomes of cefiderocol treatment during an outbreak of NDM-CRAB infections.
  • To evaluate the clinical effectiveness of cefiderocol in a real-world setting.
  • To assess the in vitro activity of cefiderocol against NDM-CRAB isolates.

Main Methods:

  • Retrospective case series of patients with NDM-CRAB colonization and/or infection.
  • Analysis of clinical outcomes, including clinical cure and mortality.
  • In vitro susceptibility testing of cefiderocol against clinical isolates using commercial assays.

Main Results:

  • Thirty-eight patients were colonized and/or infected with NDM-CRAB.
  • Thirteen patients developed systemic infections (VAP and BSIs).
  • A clinical cure was achieved in 10 (83%) patients by day 7.
  • In vitro cefiderocol activity did not consistently correlate with in vivo effectiveness.
  • Overall mortality remained high, particularly in severely ill patients.

Conclusions:

  • Cefiderocol may be a viable treatment option for NDM-CRAB infections, especially when other options are limited.
  • High clinical cure rates were observed, but overall mortality necessitates cautious use.
  • Implementation of cefiderocol susceptibility testing and robust infection control measures is crucial.